THYROSAFE- potassium iodide tablet United States - English - NLM (National Library of Medicine)

thyrosafe- potassium iodide tablet

recipharm ab (publ) - potassium iodide (unii: 1c4qk22f9j) (iodide ion - unii:09g4i6v86q) - potassium iodide 65 mg - thyroid blocking use helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. use along with other emergency measures recommended by public officials.

MONTELUKAST tablet, film coated
MONTELUKAST tablet, chewable United States - English - NLM (National Library of Medicine)

montelukast tablet, film coated montelukast tablet, chewable

recipharm pharmaservices private limited - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. hypersensitivity to any component of this product. pregnancy   category   b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed. teratogenic   effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs

FLUTIFORM 505 Israel - English - Ministry of Health

flutiform 505

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.

FLUTIFORM 1255 Israel - English - Ministry of Health

flutiform 1255

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.